Publication Date:
2021
Short description:
Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases / Canino, F.; Pugliese, G.; Baldessari, C.; Greco, S.; Depenni, R.; Dominici, M.. - In: TUMORI. - ISSN 0300-8916. - 107:6(2021), pp. NP123-NP126. [10.1177/03008916211040559]
abstract:
Immune-related myasthenia gravis is a rare, disabling, and potentially fatal adverse event of immune checkpoint inhibitor treatment. It is important to identify and manage it promptly. We present two cases of immune-related de novo myasthenia gravis observed at the Modena Cancer Center in two elderly patients treated with two anti-PD-1 monoclonal antibodies: cemiplimab and nivolumab.
Iris type:
Articolo su rivista
Keywords:
cemiplimab; immune-related adverse events; Immunotherapy; myasthenia gravis; nivolumab
List of contributors:
Canino, F.; Pugliese, G.; Baldessari, C.; Greco, S.; Depenni, R.; Dominici, M.
Published in: